Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grace Muzanyi

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Infectious Diseases|May 30, 2025
Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical TrialsRuth N Moro, John L Johnson, Neil Martinson, et al.
Plos One|May 3, 2013
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatmentMary A De Groote, Payam Nahid, Leah Jarlsberg, et al.
Tuberculosis (Edinburgh, Scotland)|March 18, 2014
Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosisPayam Nahid, Erin Bliven-Sizemore, Leah G Jarlsberg, et al.
Annals of the American Thoracic Society|March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatmentCraig M Hales, Charles M Heilig, Richard Chaisson, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Contemporary Clinical Trials|September 7, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB designEkaterina V Kurbatova, Kelly E Dooley, Wendy Carr, et al.
The New England Journal of Medicine|May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Infectious Diseases|May 30, 2025
Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical TrialsRuth N Moro, John L Johnson, Neil Martinson, et al.
Plos One|May 3, 2013
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatmentMary A De Groote, Payam Nahid, Leah Jarlsberg, et al.
Tuberculosis (Edinburgh, Scotland)|March 18, 2014
Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosisPayam Nahid, Erin Bliven-Sizemore, Leah G Jarlsberg, et al.
Annals of the American Thoracic Society|March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatmentCraig M Hales, Charles M Heilig, Richard Chaisson, et al.
The Journal of Infectious Diseases|August 2, 2012
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortiumSusan E Dorman, Stefan Goldberg, Jason E Stout, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Contemporary Clinical Trials|September 7, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB designEkaterina V Kurbatova, Kelly E Dooley, Wendy Carr, et al.
The New England Journal of Medicine|May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 2